Unscripted the AMCP Podcast: HER2-Positive Biliary Tract Cancer
HER2-Positive Biliary Tract Cancer: Biomarkers, T…
Healthcare NOW Radio Podcast Network - Discussions on healthcare including technology, innovation, policy, data security, telehealth and more. Visit HealthcareNOWRadio.com · Healthcare NOW Radio and Podcast Network - Radio and Podcasts for the Healthcare Industry
March 25, 202613m 33s
Audio is streamed directly from the publisher (podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
HER2-Positive Biliary Tract Cancer: Biomarkers, Targeted Therapy, and Managed Care Access
On this episode, Jeffrey Dunn, PharmD, MBA, President and CEO of Cooperative Benefits Group, discusses the rapidly evolving treatment landscape for HER2-positive biliary tract cancer (BTC) and its implications for managed care. The discussion covers the importance of biomarker testing and molecular profiling in guiding targeted therapy, key NCCN guideline considerations across lines of treatment, and the clinical and economic impact of timely access to HER2-directed therapies. We also discuss payer-provider collaboration strategies to improve testing, coverage alignment, and patient access in this rare and aggressive form of cancer.
Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/